The functional state of CD8+ T cells determines the therapeutic efficacy of PD-1 blockade
antibodies in
tumors.
Amino acids are key nutrients for maintaining T cell antitumor immunity. In this study, we used samples from
lung cancer patients treated with PD-1 blockade
antibodies to assay the
amino acids in their serum by mass spectrometry. We found that
lung cancer patients with high serum
taurine levels generally responded to PD-1 blockade antibody
therapy, in parallel with the secretion of high levels of cytotoxic
cytokines (IFN-γ and TNF-α). CD8+ T cells cultured with exogenous
taurine exhibited decreased apoptosis, enhanced proliferation, and increased secretion of cytotoxic
cytokines. High SLC6A6 expression in CD8+ T cells was positively associated with an effector T cell signature. SLC6A6 knockdown limited the function and proliferation of CD8+ T cells.
RNA sequencing revealed that SLC6A6 knockdown altered the calcium signaling pathway, oxidative phosphorylation, and
T cell receptor signaling in CD8+ T cells. Furthermore,
taurine enhanced T cell proliferation and function in vitro by stimulation of PLCγ1-mediated
calcium and MAPK signaling.
Taurine plus
immune checkpoint blockade antibody significantly attenuated
tumor growth and markedly improved the function and proliferation of CD8+ T cells in a mouse
tumor model. Thus, our findings indicate that
taurine is an important driver for improving CD8+ T cell immune responses and could serve as a potential therapeutic agent for
cancer patients.